SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease

Journal of Neuroimaging

Volumn 16, Issue 1, 2006, Pages 16-23

  Shimizu, Soichiro ^a   Hanyu, Haruo ^a   Iwamoto, Toshihiko ^a   Koizumi, Kiyoshi ^a   Abe, Kimihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Donepezil; Frontal lobe; Regional cerebral blood flow; Single photon emission computed tomography

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; IOFETAMINE I 123;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN FUNCTION; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRONTAL LOBE; HUMAN; IMAGE ANALYSIS; LIMBIC CORTEX; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE; THREE DIMENSIONAL IMAGING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 32544445243     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2005.09.027     Document Type: Article

References (28)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
2. Rogers SL, Farlow MR, Doddy RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
3. Ebmeier KP, Hunter R, Curran SM, et al. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology (Berl) 1992;108:103-109.
4. Tune L, Tiseo PJ, Ieni J, et al Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003;11:169-177.
5. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001;42:1441-1445.
6. Nobili F, Vitali P, Canfora M, et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 2002;113:1241-1248.
7. Hanyu H, Shimizu T, Tanaka Y, Takasaki M, Koizumi K, Abe K. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2003;15:177-182.
8. Riekkinen PJr, Riekkinen M, Soininen H, Kuikka J, Laakso M, Riekkinen P Sr. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Neuroreport 1997;8:1845-1859.
9. Vennerica A, Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002;13:83-87.
10. Nobili F, Koulibaly M, Vitali P, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002;43:983-990.
11. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238-1248.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
15. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000;11:299-313.
16. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:295-300.
17. Talairach J, Tournoux P. Co-planar Stereotactic Atlas of the Human Brain. New York: Thieme, 1998.
18. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: Linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-1537.
19. Mizumura S, Kumita S, Cho K, Ishihara M, Nakajo H, Toba M, Kumazaki T. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003;17:289-295.
20. Hunter R, Wyper DJ, Patterson J, Hansen MT, Goodwin GM. Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography. Br J Psychiatry 1991;158:351-357.
21. Muir JL, Everitt BJ, Robbins TW. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J Neurosci 1994;14:2313-2326.
22. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 1994;14:167-186.
23. Warburton DM, Rusted JM. Cholinergic control of cognitive resources. Neuropsychobiology 1993;28:43-46.
24. Muir JL, Everitt BJ, Robbins TW. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology (Berl) 1995;118:82-92.
25. Vidal C. Nicotinic potentiation of glutaminergic synapsesin the prefrontal cortex: New insight into the analysis of the role of nicotinicreceptors in cognitive functions. Drug Dev Res 1994;31:120-126.
26. Sahakian BJ, Owen AM, Morant NJ, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 1993;110:395-401.
27. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
28. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350:232-233.